SDC 1: Effect of prophylactic intravenous administration of 5-HT3 antagonists on hemodynamic variables: incidence of hypotension, pooled result of obstetric and non-obstetric studies that used ondansetron.

	5HT3		Placebo		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Pirat 200514	7	50	4	50	5.0%	1.75 [0.55, 5.61]	
Kelsaka 2006 ¹⁵	0	25	3	25	1.1%	0.14 [0.01, 2.63]	· · · · · · · · · · · · · · · · · · ·
Owczuk 200817	1	36	7	35	2.1%	0.14 [0.02, 1.07]	
Shakya 201019	9	40	8	40	7.2%	1.13 [0.48, 2.62]	
Sahoo 201220	2	26	11	26	3.9%	0.18 [0.04, 0.74]	
Marashi 2014 ²¹	0	140	12	70	1.2%	0.02 [0.00, 0.34]	←
Ortiz-Gomez 20148	52	96	14	32	11.3%	1.24 [0.80, 1.91]	
Safavi 201422	3	40	9	40	4.7%	0.33 [0.10, 1.14]	
Wang M 2014 ²³	44	118	18	30	11.9%	0.62 [0.43, 0.90]	
Wang Q 2014 ²⁴	8	33	18	32	8.8%	0.43 [0.22, 0.85]	
Marciniak 201527	14	36	15	36	9.9%	0.93 [0.53, 1.64]	-
Owczuk 2015 ²⁸	10	26	13	27	9.3%	0.80 [0.43, 1.49]	
Trabelsi 20157	15	40	31	40	11.3%	0.48 [0.31, 0.75]	-
Terkawi 201525	26	42	25	41	12.2%	1.02 [0.72, 1.43]	+
Total (95% CI)		748		524	100.0%	0.67 [0.48, 0.92]	•
Total events	191		188				
Heterogeneity: Tau ² =	0.20; Chi ²	= 37.4	7, df = 13	(P = 0	.0003); l ² :	= 65%	
Test for overall effect:	Z = 2.46 (I	P = 0.0	1)			Fa	0.01 0.1 1 10 1 vors 5HT3 antagonist Favors placebo